Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1995-12-12
|
| pubmed:abstractText |
Preliminary studies in allogeneic BMT suggest that recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is well tolerated. This is a prospective, multicenter, randomized, double-blind, placebo-controlled trial. Yeast-derived rhGM-CSF 250 micrograms/m2/day or placebo was administered by 4-hour i.v. infusion starting on the day of marrow infusion (day 0) to day 20. All patients received HLA-identical sibling marrow and cyclosporine and prednisone for GVHD prophylaxis. Fifty three patients received rhGM-CSF and 56 received placebo. Comparison of demographics revealed no differences. The time to achieve an absolute neutrophil count of > 0.5 x 10(9) cells/l was shortened in rhGM-CSF treated patients (day 13 vs. 17, P = 0.0001). The incidences of grade III-IV mucositis and infection were significantly reduced (P = 0.005, P = 0.001, respectively) and duration of hospitalization was modestly shortened by 1 day (P = 0.02) in rhGM-CSF treated patients. No differences in platelet recovery, erythrocyte recovery, incidence of veno-occlusive disease, GVHD severity, relapse or survival were observed. In conclusion, rhGM-CSF is well tolerated and reduces post-transplant morbidity in patients undergoing HLA-identical allogeneic BMT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hematopoietic Cell Growth Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
949-54
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7581096-Adult,
pubmed-meshheading:7581096-Bone Marrow Transplantation,
pubmed-meshheading:7581096-Double-Blind Method,
pubmed-meshheading:7581096-Female,
pubmed-meshheading:7581096-Graft vs Host Disease,
pubmed-meshheading:7581096-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:7581096-HLA Antigens,
pubmed-meshheading:7581096-Hematopoietic Cell Growth Factors,
pubmed-meshheading:7581096-Hepatic Veno-Occlusive Disease,
pubmed-meshheading:7581096-Humans,
pubmed-meshheading:7581096-Infection,
pubmed-meshheading:7581096-Leukemia,
pubmed-meshheading:7581096-Leukocyte Count,
pubmed-meshheading:7581096-Lymphoma,
pubmed-meshheading:7581096-Male,
pubmed-meshheading:7581096-Multiple Myeloma,
pubmed-meshheading:7581096-Myelodysplastic Syndromes,
pubmed-meshheading:7581096-Nuclear Family,
pubmed-meshheading:7581096-Prospective Studies,
pubmed-meshheading:7581096-Recombinant Proteins,
pubmed-meshheading:7581096-Tissue Donors,
pubmed-meshheading:7581096-Transplantation, Homologous,
pubmed-meshheading:7581096-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
|
| pubmed:affiliation |
Texas Oncology, PA/Sammons Baylor, Dallas 75204, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|